How Ozempic Changed Denmark

Denmark has about six million people. It is known for wind turbines, shipping, Lego, beer and pastry. For most of the 2020s it has also been known for something else: it is the country where Ozempic comes from, and for a few years the fortunes of one company and one molecule shaped its entire national economy.

This is a story about what happens when a single product becomes that important to a country — and what happened next, when the boom cooled.

How did one drug company get so big relative to Denmark?

Novo Nordisk was never small. It has made insulin in Denmark since the 1920s and has been the country’s largest pharmaceutical company for decades [6].

But the GLP-1 boom changed the scale entirely. Novo Nordisk’s net sales went from DKK 140.8 billion in 2021 to DKK 309.1 billion in 2025 — more than doubling in four years [13]. Operating profit went from DKK 58.6 billion to DKK 127.7 billion over the same stretch.

The stock market did what stock markets do with growth like that. On September 1, 2023, Novo Nordisk overtook LVMH to become the most valuable listed company in Europe [16]. By March 2024 its market capitalization was around $604 billion, making it the twelfth most valuable company in the world.

At its peak, Novo Nordisk’s market value exceeded the entire annual gross domestic product of Denmark [6]. That is a genuinely unusual situation. There are a handful of historical parallels — Nokia in Finland in the early 2000s, for instance — and they are all cautionary.

How much of Denmark’s economy was really Novo Nordisk?

There is no single clean percentage, and anyone who gives you one is simplifying. But the individual markers are striking.

Growth. Two thirds of Denmark’s overall economic growth in 2022 was attributed to the pharmaceutical industry [6]. In 2023, when much of Europe stagnated, Novo Nordisk’s expansion was credited with keeping Danish GDP growth positive [5]. Denmark’s economy expanded 3.7% in 2024, among the strongest rates in Europe, boosted heavily by pharmaceutical exports [1].

Jobs. Novo Nordisk accounted for roughly one fifth of Denmark’s total employment growth in 2024 [1]. It employed about 34,000 people in Denmark in 2025 after nearly doubling its global workforce over five years [1]. That 34,000 figure is from August 2025 reporting, before the cuts announced the following month landed; Novo Nordisk has not published a post-restructuring Denmark-only headcount, so treat it as a pre-cut number. Globally the company’s own boilerplate put the total at about 66,700 people in August 2026 and over 67,000 in September 2026, down from 77,349 at the end of 2024 [17].

Tax. Novo Nordisk has been Denmark’s largest corporate taxpayer. Its reported income tax bill for 2023 was roughly $2.3 billion [6].

Forecasting. This is the strangest marker. Economists began treating Novo Nordisk’s quarterly results as a leading indicator of Danish GDP — an unusual situation in which one company’s earnings closely predict national accounts [4].

Danish statisticians even began publishing GDP figures both with and without the pharmaceutical sector, because including it distorted the picture of what the rest of the economy was doing.

What happened in Kalundborg?

If you want the physical rather than financial version of this story, go to Kalundborg.

Kalundborg is a town of roughly 16,000 people on the west coast of the island of Zealand, about 65 miles from Copenhagen. It is where most of the world’s semaglutide active pharmaceutical ingredient is made.

In 2023 Novo Nordisk announced it would invest more than DKK 42 billion — about 5.6 billion euros — expanding the site, most of it directed at active ingredient capacity [7]. The centerpiece is a new 170,000-square-meter multi-product facility designed to handle current and future processes. Construction was scheduled to finish gradually from the end of 2025 through 2029, with the site expected to be fully operational during 2029 and about 800 new jobs created [8].

By the end of 2025 the company had spent DKK 23.1 billion of that budget [6].

Towns like Kalundborg and Hillerod became the local face of the boom: construction cranes, housing pressure, hiring fairs, new schools. The New York Times and Bloomberg both wrote at length in 2024 about the transformation of small Danish towns by a weight loss drug that most of their residents would never take.

Were people worried about the concentration?

Yes, and openly so.

By April 2024, economists were publicly discussing the risk of Dutch disease in Denmark [6]. The term comes from the Netherlands after a natural gas boom in the 1960s: one sector booms, currency and wages rise, other export industries become uncompetitive, and when the boom ends the country finds it has hollowed out everything else.

Denmark’s version was not about gas but about peptides. The concerns raised at the time were concrete:

• A rising krone and rising wages squeezing other Danish exporters
• Skilled workers being pulled out of other sectors into pharmaceutical construction and manufacturing
• Public finances becoming dependent on the tax receipts of one company
• National statistics becoming hard to interpret

Denmark had real defenses. It is a diversified exporter with Maersk in shipping, Vestas in wind, Carlsberg in brewing, Lego in toys and Novonesis in enzymes, plus a large savings surplus and strong public finances [1]. But the exposure was genuine.

What happened when the boom cooled?

Denmark found out in 2025.

Novo Nordisk cut its own forecasts three times that year. It lost the lead in the US obesity market to Eli Lilly’s tirzepatide. Its share price fell 48% over the calendar year, from DKK 624 to DKK 325 [13].

The macro effect came fast. On August 29, 2025, Denmark’s economy ministry cut its 2025 GDP growth forecast from 3% to 1.4%, explicitly citing weaker prospects for Novo Nordisk alongside US tariffs on Danish goods [2][1]. Export growth expectations for the year were slashed from 4.3% to 0.9%, after a sharp decline in exports to the United States in the first half of the year.

“The pharmaceutical industry is increasingly challenged by competition in the markets for weight loss products, which has dampened growth expectations in the industry,” the ministry said [1].

Then came the jobs. On September 10, 2025, Novo Nordisk announced it would cut about 9,000 positions worldwide, roughly 11% of its workforce — including about 5,000 in Denmark [9]. It was reported at the time as the largest single round of job losses in Danish corporate history.

Reuters reporting from inside the company that October described the mood among Danish staff, with workers referring to the affected group as “Club 5,000.” Cuts hit packaging teams at Hillerod that had been preparing new production lines for Wegovy and Ozempic, lines that were supposed to ramp up in 2026 [10].

Denmark’s economy ministry expected the redundancies to show up in unemployment figures during the first half of 2026, after notice periods expired [14].

The Novo Nordisk Foundation felt it too. Novo Holdings, which manages the Foundation’s wealth and is the vehicle through which it controls Novo Nordisk, reported that assets under management fell 34% in 2025, from DKK 1,060 billion to DKK 694 billion — almost entirely because of the drop in Novo Nordisk’s market value [11]. The Foundation still awarded DKK 11.8 billion in grants that year, but the pool it draws from had shrunk sharply.

Why does a charity own the company that makes Ozempic?

This is the part of the Danish story that most puzzles American readers, and it is central to how everything above played out.

Novo Nordisk is controlled by the Novo Nordisk Foundation, a Danish enterprise foundation whose articles of association legally require it to maintain a controlling interest in the company [12]. It does so through a wholly owned holding company, Novo Holdings.

At the end of 2025, Novo Holdings held about 28.1% of Novo Nordisk’s share capital and about 77.3% of its votes [12]. The gap exists because of a dual-class share structure: unlisted A shares held only by Novo Holdings carry far more voting power than the ordinary B shares that trade publicly, and the Foundation is barred from selling them.

Enterprise foundations of this kind are common in Denmark and rare elsewhere. Roughly a quarter of the largest Danish companies are controlled this way. The theory is that it insulates companies from short-term market pressure and keeps ownership, and profits, anchored in the country.

In 2025 it also meant that when the controlling owner decided change was needed, it happened fast and in public: a chief executive out in May, a new one in August, most of the board replaced at a special shareholder meeting in November.

Where does Denmark stand now?

Better than the 2025 panic suggested, but permanently more aware of the risk.

Denmark raised its 2026 GDP growth forecast to 2.1% from 1.4%, partly on expectations of higher private and public spending [1]. In March 2026 Danske Bank projected that Denmark’s economy would still expand faster than any of its Nordic neighbors that year, even with Novo Nordisk’s sales slowing [15].

Novo Nordisk itself stabilized somewhat. It raised its 2026 guidance twice, in May and August, on the strength of the Wegovy pill launch, ending up guiding to adjusted sales growth of 0% to -6% at constant exchange rates for the year. It is still enormously profitable and it is still building — the Kalundborg expansion runs to 2029. The share price has not recovered: the B shares closed at DKK 276 on September 11, 2026, down a further 15% for the year to date after 2025’s 48% fall.

The company is also relaunching itself publicly. On September 14, 2026 it announced a rebrand to the single name “Novo” with the line “Lasting Health Starts Now,” keeping Novo Nordisk A/S as its legal name and the Apis bull logo, and set out a new internal culture ahead of a Capital Markets Day in London on September 21 where it promised updated long-term financial targets [17]. For Denmark, those targets are the number to watch: they are effectively a forecast for a meaningful slice of the country’s export growth.

But the arc is now visible to everyone in Denmark. A country got a windfall from one molecule, restructured a slice of its economy around it, and then discovered how quickly that kind of concentration can reverse. The debate in Copenhagen has shifted from how to manage a boom to how to build the industries that come after it.

What does this mean if you take semaglutide?

Very little, directly, and that is worth saying plainly.

The Danish economic story explains why Novo Nordisk built so much capacity so fast, why Danish towns changed shape, and why a company earnings call moves a country’s statistics. It does not change what the medicine does or whether it is right for you.

The one practical thread is supply. The enormous Danish and American manufacturing build-out is the reason the semaglutide shortage that defined 2023 and 2024 ended, and the reason the company could launch two new formats in 2026. Capacity built during a boom is still capacity.

Everything else about whether to take a GLP-1 medicine — the benefits, the side effects, the cost, the alternatives — is a conversation for you and a healthcare provider.

Sources

1. Novo Nordisk woes prompt Denmark to slash country’s 2025 growth forecast — Reuters via Global Banking and Finance Review, August 29, 2025
2. Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown — CNBC, August 29, 2025
3. Novo Nordisk’s woes are slimming Denmark’s economic growth — The New York Times, September 22, 2025
4. The Novo Nordisk economy: Denmark’s growing dependence on a single pharma giant — Columbia Economic Review
5. Novo Nordisk’s Wegovy and Ozempic boom saved Denmark’s GDP from a no-growth 2023 — Fortune, March 5, 2024
6. Novo Nordisk — Wikipedia (history, market capitalization milestones, Dutch disease commentary, tax history)
7. Novo Nordisk to invest 5.6 billion euros in expansion of API production in Denmark — CHEManager
8. Novo Nordisk’s API manufacturing facility, Kalundborg, Denmark — Pharmaceutical Technology
9. Novo Nordisk to lay off 9,000 workers in major restructuring — BioPharma Dive, September 10, 2025
10. Inside Novo Nordisk’s ‘Club 5,000’ as Danish staff cuts gain pace — Reuters, October 15, 2025
11. Novo Holdings announces 2025 annual results — Novo Holdings A/S, March 12, 2026
12. Ownership — Novo Nordisk Foundation
13. Five-year overview, Novo Nordisk Annual Report 2025 — Novo Nordisk A/S
14. Novo Nordisk layoffs add fuel to Denmark’s economic anxieties — Financial Post / Bloomberg, February 19, 2026
15. Danish economy to outpace Nordics despite Novo woes, Danske says — Bloomberg, March 4, 2026
16. Novo Nordisk briefly overtakes LVMH as Europe’s most valuable company — Reuters, September 1, 2023
17. Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture — Novo Nordisk via GlobeNewswire, September 14, 2026